Daily Sepsis Research Analysis
Analyzed 32 papers and selected 3 impactful papers.
Summary
Rapid diagnostics, methodological transparency, and immune-pathway insights dominate today’s sepsis literature. A portable automated cfDNA platform enables same-day metagenomic pathogen identification, an open-source tool (Equiflow) exposes hidden cohort selection biases in AI studies, and multi-omics work highlights T/NK-cell–related hub genes (DDX24, GZMM) with diagnostic and prognostic relevance.
Research Themes
- Rapid metagenomic diagnostics via cfDNA and nanopore sequencing
- Transparent and bias-aware cohort construction for clinical AI
- Immune dysregulation biomarkers (T/NK cell pathways) in sepsis
Selected Articles
1. An automated and portable platform for rapid cell-free DNA isolation and its application in microbial DNA metagenomic sequencing from human blood samples.
A portable automated platform (CNASafe) achieved cfDNA extraction in 40 minutes with average relative recovery of 100.5% across 333 extractions, equivalent to a reference kit. In 10 patient samples, nanopore sequencing of cfDNA enabled identification of pathogens missed by blood cultures or confirmation of negative cultures, supporting hours-scale decentralized metagenomic diagnostics.
Impact: This engineering advance directly addresses time-to-diagnosis in sepsis by enabling rapid, decentralized cfDNA-based metagenomics with performance comparable to reference methods.
Clinical Implications: Hospitals and critical care settings could implement same-day metagenomic pathogen identification to guide targeted antimicrobial therapy, particularly when cultures are slow or negative.
Key Findings
- Automated cfDNA extraction completed in 40 minutes vs 75 minutes for reference protocol.
- Average relative cfDNA recovery was 100.5% across 333 extractions, equivalent to QIAamp Circulating Nucleic Acid Kit.
- Nanopore sequencing of cfDNA from 10 patient samples identified pathogens missed by blood cultures or confirmed negative results.
- Platform supports hours-scale deployment of metagenomic diagnostics in decentralized environments.
Methodological Strengths
- Extensive bench validation across 333 extractions with head-to-head comparison to a reference kit.
- Demonstrated clinical feasibility using real patient samples and real-time nanopore sequencing.
Limitations
- Clinical validation cohort was small (10 samples) and did not assess antimicrobial resistance profiling.
- Regulatory pathways, cost-effectiveness, and workflow integration were not evaluated.
Future Directions: Prospective multicenter trials should assess clinical impact on time-to-appropriate-therapy, outcomes, and stewardship; integration with resistance genotyping and standardized reporting is needed.
The prompt identification of pathogens in human circulation in a clinically deployable format remains an unmet clinical need. The established test for infection diagnostics remains blood culture, which typically takes 2-4 days and is positive in less than 15% of cases, with many prevalent pathogens difficult or impossible to culture. While microbial cfDNA in blood could facilitate the diagnosis of sepsis, febrile and infectious conditions, sample preparation for cell-free DNA (cfDNA) analysis in decentralised settings presents challenges due to its complexity and the low concentration and fragmented nature of cfDNA in blood plasma. We developed a portable and automated platform and a consumable (CNASafe) for cfDNA isolation from human plasma samples. The platform-device performance was evaluated by comparing relative cfDNA yield against a reference (QIAGEN QIAamp Circulating Nucleic Acid Kit). cfDNA eluates from ten non-cultured blood samples from hospital patients were sequenced on a nanopore sequencer, and results compared to blood cultures.
2. Equiflow: An open-source software package for evaluating changes in cohort composition.
Equiflow standardizes and visualizes cohort selection, quantifying distributional shifts caused by exclusions and preprocessing. In a large eICU sepsis case study, the cohort shrank from 126,750 to 1,094, and enforcing non-missing troponin produced substantial demographic shifts that typical reporting would miss.
Impact: By making hidden selection biases explicit before modeling, Equiflow advances methodological rigor and fairness in clinical AI, directly relevant to sepsis research using large EHR datasets.
Clinical Implications: Improved transparency in cohort construction can prevent biased sepsis models, enhance external validity, and support equitable deployment of decision-support tools.
Key Findings
- Automated flow diagrams track both sample size and composition throughout selection.
- Quantifies distributional shifts at each exclusion step with visualizations.
- In eICU sepsis data, exclusions reduced cases from 126,750 to 1,094, with final troponin filtering inducing major demographic shifts.
- Open-source standardization promotes reproducibility and bias disclosure.
Methodological Strengths
- Open-source tool enabling reproducibility and standard reporting of cohort selection.
- Applied to a very large real-world sepsis dataset highlighting hidden biases.
Limitations
- No prospective demonstration that using Equiflow improves clinical outcomes or model performance.
- Single database case study; generalizability across settings and variables not fully evaluated.
Future Directions: Integrate Equiflow into prospective AI model development pipelines and report its impact on model fairness, calibration, and transportability across institutions.
Clinical research studies routinely apply exclusion criteria and data preprocessing steps that can substantially alter dataset composition, potentially introducing hidden biases that affect validity and generalizability. This is particularly important in artificial intelligence/machine learning (AI/ML) studies where models learn patterns directly from training data. We developed Equiflow, an open-source Python package that automates creation of enhanced participant flow diagrams tracking both sample size and composition changes throughout studies. Equiflow quantifies distributional shifts at each exclusion step and generates visualizations showing how key clinical and demographic variables evolve during participant selection. In a case study of sepsis patients from the eICU database, sequential exclusions reduced the sample from 126,750-1,094 patients. Requiring non-missing troponin measurements in the final step of data processing caused substantial demographic shifts that would typically remain invisible in traditional reporting.
3. Immunomodulatory Roles and Clinical Significance of GZMM and DDX24 in Sepsis: A Multiomics Integrative Analysis With Experimental Validation.
Integrative transcriptomic analyses identified downregulated hub genes (DDX24, GZMM, KCNA3, NCL) in sepsis, with qRT-PCR validation. DDX24 showed strong diagnostic performance, while GZMM associated with prognosis and APACHE II, consistent with T/NK-cell exhaustion signatures from single-cell data.
Impact: This study connects specific T/NK-cell–related genes with diagnostic and prognostic signals in sepsis, offering mechanistic insight and testable targets for immune-modulating strategies.
Clinical Implications: DDX24 and GZMM may inform risk stratification and biomarker panels; findings prioritize T/NK-cell pathways for future immunotherapies and adaptive immune monitoring in sepsis.
Key Findings
- Identified four hub genes (DDX24, GZMM, KCNA3, NCL) downregulated in sepsis across multiple GEO datasets using ML, WGCNA, and PPI analyses.
- qRT-PCR validated significant downregulation of all four genes in sepsis patients; DDX24 achieved diagnostic AUC > 0.8.
- GZMM expression associated with patient prognosis and APACHE II scores; single-cell data linked DDX24/GZMM to T/NK-cell exhaustion signatures.
- In silico drug prediction yielded 25 candidate compounds for potential precision therapeutics.
Methodological Strengths
- Multi-dataset integration (bulk and single-cell) with complementary algorithms (ML, WGCNA, PPI).
- Orthogonal qRT-PCR validation in patient samples enhances robustness.
Limitations
- Primarily observational transcriptomic analyses without in vivo functional validation.
- External prospective validation and clinical assay standardization are lacking.
Future Directions: Functional studies to define causal roles of DDX24/GZMM in T/NK-cell dysfunction and prospective validation of biomarker panels in diverse sepsis cohorts.
Sepsis is a systemic inflammatory response syndrome caused by an infection featuring high morbidity and mortality due to complex mechanisms underlying immune dysfunction. In this study, based on the sepsis transcriptome profiles from the GEO datasets (GSE65682, GSE28750, GSE95233, and GSE167363), we used the machine learning method and other computational algorithms, such as differential gene expression analysis, weighted gene coexpression network analyses (WGCNA), and the building of PPI networks to identify four hub genes (DDX24, GZMM, KCNA3, and NCL). The quantitative reverse transcription PCR performed preliminary validation that all four hub genes were significantly downregulated in patients with sepsis. DDX24 had the highest diagnostic performance (AUC > 0.8) for discriminating patients from normal subjects. GZMM was found to be significantly related to the prognoses of patients as well as APACHE II scores, and the downregulated expression pattern might represent T cell and NK cell exhaustion. Analysis based on single-cell RNA sequencing showed that DDX24 and GZMM were mainly expressed in T cells and NK cells, and the expression trends strongly correlate with patient survival.